
CRDL
Cardiol Therapeutics Inc
- Overview
- Forecast
- Valuation
- Earnings

Line
|

Candle
1D
5D
1M
3M
6M
YTD
1Y
5Y
High
1.590
Open
1.490
VWAP
--
Vol
927.19K
Mkt Cap
126.45M
Low
1.400
Amount
--
EV/EBITDA(TTM)
--
Total Shares
69.00M
EV
150.42M
EV/OCF(TTM)
--
P/S(TTM)
--
Cardiol Therapeutics Inc. is a Canada-based clinical-stage life sciences company focused on developing anti-inflammatory and anti-fibrotic therapies for the treatment of heart disease. The Company's lead small-molecule drug candidate, CardiolRx (cannabidiol) oral solution, is pharmaceutically manufactured and in clinical development for use in the treatment of heart disease. It holds investigational new drug application authorization from the United States Food and Drug Administration (US FDA) to conduct clinical studies to evaluate the efficacy and safety of CardiolRx in two diseases affecting the heart: recurrent pericarditis and acute myocarditis. The MAVERIC Program in recurrent pericarditis, an inflammatory disease, comprises the completed Phase II MAvERIC-Pilot study (NCT05494788) and the ongoing Phase III MAVERIC trial (NCT06708299). The Company is also developing CRD-38, a novel subcutaneously administered drug formulation intended for use in heart failure.
Show More
2 Analyst Rating

455.56% Upside
Wall Street analysts forecast CRDL stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for CRDL is 8.50 USD with a low forecast of 8.00 USD and a high forecast of 9.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
2 Buy
0 Hold
0 Sell
Moderate Buy

455.56% Upside
Current: 1.530

Low
8.00
Averages
8.50
High
9.00

455.56% Upside
Current: 1.530

Low
8.00
Averages
8.50
High
9.00
H.C. Wainwright
H.C. Wainwright
Buy
initiated
$9
2025-06-02
Reason
H.C. Wainwright
H.C. Wainwright
Price Target
$9
2025-06-02
initiated
Buy
Reason
H.C. Wainwright initiated coverage of Cardiol Therapeutics with a Buy rating and $9 price target. Cardiol is a clinical-stage company focused on developing anti-inflammatory and anti-fibrotic therapies for heart disease, the analyst tells investors in a research note. The firm says Cardiol is currently advancing CardiolRx in two lead programs that target recurrent pericarditis and acute myocarditis. It believes investors could soon come to appreciate the value to be unlocked within the company.
HC Wainwright & Co.
Vernon Bernardino
Strong Buy
Reiterates
$9
2025-04-16
Reason
HC Wainwright & Co.
Vernon Bernardino
Price Target
$9
2025-04-16
Reiterates
Strong Buy
Reason
HC Wainwright & Co.
Vernon Bernardino
Strong Buy
Reiterates
$9
2025-04-07
Reason
HC Wainwright & Co.
Vernon Bernardino
Price Target
$9
2025-04-07
Reiterates
Strong Buy
Reason
HC Wainwright & Co.
Vernon Bernardino
Strong Buy
Reiterates
$9
2025-02-24
Reason
HC Wainwright & Co.
Vernon Bernardino
Price Target
$9
2025-02-24
Reiterates
Strong Buy
Reason
HC Wainwright & Co.
Vernon Bernardino
Strong Buy
Reiterates
$9
2024-12-18
Reason
HC Wainwright & Co.
Vernon Bernardino
Price Target
$9
2024-12-18
Reiterates
Strong Buy
Reason
HC Wainwright & Co.
Vernon Bernardino
Strong Buy
Reiterates
$9
2024-11-20
Reason
HC Wainwright & Co.
Vernon Bernardino
Price Target
$9
2024-11-20
Reiterates
Strong Buy
Reason
See All Ratings
Valuation Metrics
The current forward P/E ratio for Cardiol Therapeutics Inc (CRDL.O) is -3.87, compared to its 5-year average forward P/E of -4.33. For a more detailed relative valuation and DCF analysis to assess Cardiol Therapeutics Inc 's fair value, click here.
Forward PE
The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.

N/A
5Y Average PE
-4.33
Current PE
-3.87
Overvalued PE
-2.30
Undervalued PE
-6.36
Forward EV/EBITDA
The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.

N/A
5Y Average EV/EBITDA
-3.83
Current EV/EBITDA
-5.49
Overvalued EV/EBITDA
-0.87
Undervalued EV/EBITDA
-6.79
Forward PS
The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.

N/A
5Y Average PS
26.03
Current PS
0.00
Overvalued PS
94.46
Undervalued PS
-42.40
Financials
Annual
Quarterly
FY2025Q1
N/A
Total Revenue
FY2025Q1
YoY :
+0.28%
-8.43M
Operating Profit
FY2025Q1
YoY :
-9.72%
-8.29M
Net Income after Tax
FY2025Q1
YoY :
-28.57%
-0.10
EPS - Diluted
FY2025Q1
YoY :
+3.46%
-7.17M
Free Cash Flow
FY2025Q1
N/A
Gross Profit Margin - %
FY2025Q1
N/A
Net Margin - %
Trading Trends
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
0-3
Months
0.0
USD
0
3-6
Months
0.0
USD
0
6-9
Months
0.0
USD
0
0-12
Months
0.0
USD
0
Bought
0-3
0
0.0
USD
Months
3-6
0
0.0
USD
Months
6-9
0
0.0
USD
Months
0-12
0
0.0
USD
Months
Hedge Fund
Hedge Funds are Neutral. There are no significant trading trends over the last quarter.
Sold
0-3
Months
0.0
Volume
0
3-6
Months
0.0
Volume
0
6-9
Months
0.0
Volume
0
0-12
Months
0.0
Volume
0
Bought
0-3
0
0.0
Volume
Months
3-6
0
0.0
Volume
Months
6-9
0
0.0
Volume
Months
0-12
0
0.0
Volume
Months
Congress Trading
Congress are Neutral. There are no significant trading trends over the last month.
Sold
0-3
Months
0.0
USD
0
3-6
Months
0.0
USD
0
6-9
Months
0.0
USD
0
0-12
Months
0.0
USD
0
Bought
0-3
0
0.0
USD
Months
3-6
0
0.0
USD
Months
6-9
0
0.0
USD
Months
0-12
0
0.0
USD
Months
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
0-3
Months
0.0
USD
0
3-6
Months
0.0
USD
0
6-9
Months
0.0
USD
0
0-12
Months
0.0
USD
0
Bought
0-3
0
0.0
USD
Months
3-6
0
0.0
USD
Months
6-9
0
0.0
USD
Months
0-12
0
0.0
USD
Months
CRDL News & Events
News
9.0
07-22NASDAQ.COMCardiol To Report ARCHER Study Data Within The Next Two Weeks
4.0
06-02BenzingaThis Visa Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Monday
4.0
06-02BenzingaHC Wainwright & Co. Initiates Coverage On Cardiol Therapeutics with Buy Rating, Announces Price Target of $9
Sign Up For More News
People Also Watch

MDXH
MDxHealth SA
2.540
USD
+2.01%

SUNS
Sunrise Realty Trust Inc
10.520
USD
+0.38%

MGX
Metagenomi Inc
2.515
USD
+3.50%

LPTX
Leap Therapeutics Inc
0.340
USD
-5.56%

LNSR
LENSAR Inc
13.110
USD
+0.46%

FRD
Friedman Industries Inc
15.220
USD
-1.68%

HNNA
Hennessy Advisors Inc
12.580
USD
-2.40%

RECT
Rectitude Holdings Ltd
4.850
USD
+2.13%

SDST
Stardust Power Inc
0.461
USD
-12.54%
FAQ

What is Cardiol Therapeutics Inc (CRDL) stock price today?
The current price of CRDL is 1.53 USD — it has increased 6.25 % in the last trading day.

What is Cardiol Therapeutics Inc (CRDL)'s business?

What is the price predicton of CRDL Stock?

What is Cardiol Therapeutics Inc (CRDL)'s revenue for the last quarter?

What is Cardiol Therapeutics Inc (CRDL)'s earnings per share (EPS) for the last quarter?

What changes have occurred in the market's expectations for Cardiol Therapeutics Inc (CRDL)'s fundamentals?

How many employees does Cardiol Therapeutics Inc (CRDL). have?
